Skip to content

Entrada Therapeutics, Inc.

TRDA· NasdaqCore metricsCIK 1689375

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · -4.95%
Market cap
$203.19M
39.15M shares
Filings
474
$905.00K
Q3 2026−87.9% FY25 yoy
-$39.74M
Q3 2026N/M FY25 yoy
-$41.69M
Q3 2026N/M FY25 yoy
-$104.34M
Q3 2026derivedN/M FY25 yoy
-$0.94
Q3 2026N/M FY25 yoy
$112.24M
Q3 2026−10.7% FY25 yoy
$203.19M
—
51.1×
1.0×
-67.10%
—

Twelve months to Sep 30, 2026 · derived

Price

$5.1932.77%$2.53past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$25.42MFY 2025
$210.78M0FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$25,421,000reported
FY 20242024-12-31$210,782,000reported
FY 20232023-12-31$129,013,000reported

Pharmaceutical preparations

Entrada Therapeutics, Inc. is the 149th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Entrada Therapeutics, Inc. · CIK 1689375 · Engraved from SEC EDGAR